Policy & Regulation
-
Andrew Harnik via Getty Images
The end of MAHA?; Inovio’s big FDA win
American voters turned their noses up at MAHA-aligned candidates this week; Inovio won a breakthrough nod for a DNA-based therapy.
By PharmaVoice Staff • Nov. 6, 2026 -
Jon Cherry via Getty Images
Ramaswamy’s biotech baggage haunted his political run
A pivotal Alzheimer’s trial tied to Vivek Ramaswamy’s political rise is a tale of failed endpoints.
By Sy Mukherjee • Nov. 5, 2026 -
Explore the Trendline➔
Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
Salwan Georges via Getty Images
The Democrats are coming. Here’s how they want to change pharma and healthcare.
This week’s slate of Democratic winners have set their sights on expanding healthcare, removing RFK Jr. from HHS and pulling back the curtain on Trump’s secretive pharma deals.
By Meagan Parrish • Nov. 5, 2026 -
Sarah Silbiger via Getty Images
A push for speedier drug approvals doesn’t promise smooth market sailing
Investors and payers sometimes balk at drugs approved on an accelerated pathway. Here’s how pharma can de-risk these medications while they’re still in development.
By Alexandra Pecci • Nov. 4, 2026 -
Heather Diehl/Getty Images via Getty Images
Pharma has friends in both parties this midterm season. Neither is offering a free pass.
As the industry donates and lobbies in both political directions, ongoing drug policy issues and a new head of PhRMA could complicate its traditional campaign playbook.
By Sy Mukherjee • Oct. 29, 2026 -
Getty Images
Most new drugs are still too costly at launch, ICER says
A new analysis from the non-profit group found that net launch prices for new medicines spiked significantly between 2022 and 2025, and the majority were well above its cost-effectiveness guidelines.
By Jonathan Gardner • Oct. 22, 2026 -
Getty Images
Pharma gift giving linked to writing more prescriptions — but less appropriate prescribing
The line between educating healthcare professionals and wooing them can still be fuzzy, which is impacting what doctors prescribe, according to a new analysis.
By Alexandra Pecci • Oct. 20, 2026 -
Getty Images
FDA ‘reset’ continues with new plan for reviewing rare disease drugs
A revamped regulatory framework may give investors less of a “guessing game” as they weigh chances for drug approvals, one analyst said.
By Kristin Jensen • Oct. 16, 2026 -
Getty Images
Lilly is fighting a black market for its new obesity drug even before it launches
The large pharma’s promising new candidate retatrutide is still in the clinic. But Lilly is already fighting a web of illicit sellers for the drug online.
By Kelly Bilodeau • Oct. 12, 2026 -
Getty Images
HHS’ need for R&D speed; weird GLP-1 side effects
HHS is cranking up its efforts to accelerate drug development; more reports are emerging about off target effects of obesity drugs.
By PharmaVoice Staff • Oct. 9, 2026 -
Getty Images
5 key facts about the FDA expedited IND pilot program
The program, part of Operation TrialBlazer, aims to speed early research and help the U.S. bring trials back from overseas.
By Kelly Bilodeau • Oct. 7, 2026 -
Getty Images
Top pharma industry conferences in 2027
Where pharma and biotech leaders will converge to network, share ideas and potentially strike deals.
By Meagan Parrish • Oct. 6, 2026 -
Getty Images
Basecamp raises $140M before the clinic; J&J and Compass’ potential rivalry
Some of the biggest news and trends captured in PharmaVoice’s newsletter this week. Sign up here to receive the newsletter daily. Another big AI haul Investors are still lining up to back AI drug developers before their candidates reach human trials. Basecamp Research...
By PharmaVoice Staff • Sept. 25, 2026 -
Tasos Katopodis via Getty Images
Where does FDA nominee Overton stand on vaccines and other key pharma issues?
Pressed by lawmakers on Thursday, Trump’s pick as the next FDA chief said she’d “follow the law” on vaccine-related decisions and work to speed early drug R&D.
By Jonathan Gardner • Sept. 24, 2026 -
Kevin Dietsch via Getty Images
A hidden tradeoff in Trump’s MFN drug deals
The government has announced pricing agreements with 26 pharma companies. But the deals could stymie other plans to lower the country’s drug spend.
By Kelly Bilodeau • Sept. 21, 2026 -
Getty Images
Where female participation in clinical trials has caught up — and where gaps remain
Getting more women into drug R&D remains critical for boosting health outcomes. But in some disease areas, pharma is still falling behind.
By Kelly Bilodeau • Sept. 16, 2026 -
Westy72 via Getty Images
PDUFA reauthorization offers a chance at clinical trial reforms. Will the US take it?
The reauthorization could give Congress the opportunity to help streamline clinical trials and accelerate drug research.
By Kelly Bilodeau • Sept. 14, 2026 -
Sarah Silbiger via Getty Images
FDA gains ‘continuity’ as Mikhail, Davis named permanent CBER, CDER leaders
After almost two years of turnover in the FDA’s top ranks, the new appointments should help ease concerns about more turmoil ahead, one analyst said.
By Kristin Jensen • Sept. 9, 2026 -
Scott Olson/Staff via Getty Images
Prediction markets are putting a price on pharma’s secrets. Here’s what companies need to know.
As betting expands into clinical trial outcomes, drugmakers may need to look beyond employees and scrutinize outside partners with access to sensitive information.
By Sy Mukherjee • Sept. 8, 2026 -
Justin Sullivan via Getty Images
Gilead’s growing HIV franchise; cell therapy licensing deals plummet
The FDA recently OK'd Gilead's novel HIV combo med, and cell therapy deals have fallen dramatically in two years.
By PharmaVoice Staff • Sept. 4, 2026 -
Joe Raedle via Getty Images
As measles outbreaks soar, where does drug R&D stand?
More than 25 years after it was declared eliminated, measles has surged back. But drug R&D is still in early stages and up against a tense market environment.
By Alexandra Pecci • Sept. 4, 2026 -
Getty Images
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.
By Jonathan Gardner • Sept. 3, 2026 -
Andrew Harnik via Getty Images
China’s clinical trial boom under scrutiny after 3 deaths come to light
Two House Republicans are asking the FDA to increase oversight of China-generated clinical data after three trial deaths are reported.
By Kelly Bilodeau • Sept. 3, 2026 -
Anna Moneymaker via Getty Images
Trump signs order seeking to upend childhood vaccine schedule
The executive order — which wasn’t accompanied by any new scientific evidence — aims to split the MMR vaccine into three separate shots and revives the administration’s attempt to slim down the immunization schedule.
By Delilah Alvarado • Aug. 11, 2026 -
Getty Images
Large pharmas skirt tariffs; BMS’ dealmaking drought
Big Pharmas won't get hit new levies on branded drugs; and aside from the megamerger rumors, BMS has had a relatively quiet year for M&A.
By PharmaVoice Staff • Aug. 7, 2026
